GemPharmatech Co., Ltd. (SHA:688046)
China · Delayed Price · Currency is CNY 34.35
-2.35 (-6.40%)
At close: Aug 21, 2026
GemPharmatech Revenue
GemPharmatech had revenue of 251.47M CNY in the quarter ending June 30, 2026, with 23.30% growth. This brings the company's revenue in the last twelve months to 878.13M, up 21.75% year-over-year. In the year 2025, GemPharmatech had annual revenue of 793.39M with 15.51% growth.
Revenue (ttm)
878.13M
Revenue Growth
+21.75%
P/S Ratio
16.00
Revenue / Employee
552.28K
Employees
1,590
Market Cap
14.05B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 793.39M | 106.55M | 15.51% |
| Dec 31, 2024 | 686.84M | 64.65M | 10.39% |
| Dec 31, 2023 | 622.19M | 105.64M | 20.45% |
| Dec 31, 2022 | 516.55M | 122.76M | 31.17% |
| Dec 31, 2021 | 393.79M | 131.87M | 50.35% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.56B |
| Jinyu Bio-technology | 1.53B |
| Nanjing Vazyme Biotech | 1.41B |
| BrightGene Bio-Medical Technology | 1.30B |
| Shanghai Medicilon | 1.26B |
| Acrobiosystems | 887.21M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |
| Mabwell (Shanghai) Bioscience | 745.32M |